ArticleJournal of immunology (Baltimore, Md. : 1950)2013
Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development.
Article in Journal of immunology (Baltimore, Md. : 1950), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4Oncoimmunology · 2024Article
- The Evolving Landscape of B Cells in Cancer Metastasis.Cancer research · 2023Review
- Specific Targeting of STAT3 in B Cells Suppresses Progression of B Cell Lymphoma.International journal of molecular sciences · 2023Article
- Cell-targeted vaccines: implications for adaptive immunity.Frontiers in immunology · 2023Review
- Role of fibrosarcoma-induced CD11bOncogene · 2022Article
- Nanomedicines in B cell-targeting therapies.Acta biomaterialia · 2022Review
- Exploiting B Cell Transfer for Cancer Therapy: Engineered B Cells to Eradicate Tumors.International journal of molecular sciences · 2021Review
- Vector Strategies to Actualize B Cell-Based Gene Therapies.Journal of immunology (Baltimore, Md. : 1950) · 2021Review
- HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells.Cell chemical biology · 2021Article
- CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models.Oncoimmunology · 2020Article
- Active PI3K abrogates central tolerance in high-avidity autoreactive B cells.The Journal of experimental medicine · 2019Article
- B Cell-Based Cancer Immunotherapy.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2019Article
- Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy.Nature nanotechnology · 2017Article
- Pro- and anti-tumour effects of B cells and antibodies in cancer: a comparison of clinical studies and preclinical models.Cancer immunology, immunotherapy : CII · 2016Review
- Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines.Scientific reports · 2015Article
- Trial Watch: Peptide-based anticancer vaccines.Oncoimmunology · 2015Review
- Trial Watch: Peptide vaccines in cancer therapy.Oncoimmunology · 2013Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
Ab therapy against surface Ags on tumor cells has demonstrated significant efficacy for some cancers. However, it is costly and patients frequently develop acquired resistance over time. In cases of Ab therapy resistance, T cell responses have been shown to be essential in controlling disease progression. Thus, vaccination that generates a sustained Ab response as well as a T cell response may be more effective and economical. In this article, we have developed a vaccination strategy by targeting protein Ags to B cells via a CD19 single-chain variable fragment miniAb. Using the tumor-associated Ag her-2/neu extracellular domain, we showed that the coengagement of CD19 and BCR induced full B cell activation to produce a high titer of Abs and enhanced CD4 Th2 response and CD8 T cell activation and differentiation. These Abs competitively inhibited humanized her-2/neu Ab binding and were capable of activating the complement and inhibiting human breast cancer growth in vitro. Therapeutic efficacy was demonstrated in vivo using murine mammary carcinoma models. Furthermore, four different extracellular domains of her-2/neu could be targeted to B cells to generate Abs against particular domains with different antitumor properties. This approach may offer a new avenue for vaccine development with significantly lower cost, which may be of use not only for cancer therapy but also for infectious agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.